Ultragenyx Pharmaceutical Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ultragenyx Pharmaceutical (RARE).

Price Target Range — 10 Quarters

Analyst Consensus — 21 Analysts

14Buy

7Hold

Consensus RatingBuy# Analysts21Avg. Consensus PT$47Upside to Avg. PT+199.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 15, 2026	UBS	Joon Lee	Initiate	Neutral	$16
Sep 21, 2026	Evercore ISI Group	Liisa Bayko	PT Raise	In-Line	$16→$18
Sep 21, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$32→$35
Sep 18, 2026	Morgan Stanley	Maxwell Skor	PT Raise	Equal-Weight	$18→$20
Sep 18, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$31→$32
Sep 18, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$37→$39
Sep 18, 2026	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$33→$39
Sep 17, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$28→$31
Sep 4, 2026	Goldman Sachs	Salveen Richter	PT Cut	Neutral	$28→$19
Sep 4, 2026	Barclays	Eliana Merle	PT Cut	Overweight	$43→$32
Sep 3, 2026	JP Morgan	Anupam Rama	Downgrade	Overweight→Neutral	$80→$36
Sep 3, 2026	Jefferies	Maury Raycroft	PT Cut	Buy	$77→$28
Sep 3, 2026	William Blair	Sami Corwin	Downgrade	Outperform→Market Perform	—
Sep 3, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$58→$28
Sep 3, 2026	TD Cowen	Yaron Werber	PT Cut	Buy	$49→$18
Sep 3, 2026	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$50→$18
Sep 3, 2026	Canaccord Genuity	Whitney Ijem	PT Cut	Buy	$83→$37
Sep 3, 2026	Wedbush	Laura Chico	PT Cut	Neutral	$30→$23
Sep 3, 2026	Evercore ISI Group	Liisa Bayko	Downgrade	Outperform→In-Line	$34→$16
Sep 3, 2026	Baird	Joel Beatty	Downgrade	Outperform→Neutral	$40→$16

Analyst Ratings News

PRO
UBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16

UBS analyst Joon Lee initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral rating and announces Price Target of $16.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains In-Line on Ultragenyx Pharmaceutical, Raises Price Target to $18

Evercore ISI Group analyst Liisa Bayko maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a In-Line and raises the price target from $16 to $18.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $35

Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $32 to $35.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $20

Morgan Stanley analyst Maxwell Skor maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Equal-Weight and raises the price target from $18 to $20.

Benzinga Newsdesk

Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest

FDA approves Ultragenyx's Fayuvi for Sanfilippo syndrome Type A. Review commercial plans, $3.95 million pricing.

Vandana Singh

PRO
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $39

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $37 to $39.

Benzinga Newsdesk

Ultragenyx Pharmaceutical Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Ultragenyx Pharmaceutical Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16

PRO
Evercore ISI Group Maintains In-Line on Ultragenyx Pharmaceutical, Raises Price Target to $18

PRO
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $35

PRO
Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $20

Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest

PRO
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $39

People Also Watch

People Also Watch

Ultragenyx Pharmaceutical Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Ultragenyx Pharmaceutical Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16

PROEvercore ISI Group Maintains In-Line on Ultragenyx Pharmaceutical, Raises Price Target to $18

PROBarclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $35

PROMorgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $20

Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest

PROCanaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $39

People Also Watch

People Also Watch

PRO
UBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16

PRO
Evercore ISI Group Maintains In-Line on Ultragenyx Pharmaceutical, Raises Price Target to $18

PRO
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $35

PRO
Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $20

PRO
Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $39